Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Layton BioScience Inc.

www.laytonbio.com

Latest From Layton BioScience Inc.

One Company's Distraction Is Another's Lead Product

Hoping to unfreeze investor attitudes toward the industry, biotechs are embracing product strategies with the enthusiasm of religious converts. Platforms are out; so, increasingly, is discovery. The clinic is in. Targacept and Layton Bioscience are both embracing this philosophy, which enabled their deal in which Targacept bought rights to a marketed small-molecule from cell therapist Layton.
BioPharmaceutical Strategy

NeuroNova AB

Sweden's NeuroNova has identified a convenient and accessible source of neural stem cells in the ependymal layer of the brain. The company hopes to use such cells for transplantation therapy in Parkinson's disease and as a platform for drug discovery.
Regenerative Medicine

Redefining the Stem Cell Opportunity

Small companies are now trying to leverage the value of both embryonic stem cells and adult stem cells, as genomics tools and for toxicology screening. At the same time, stem cells are gradually making their way into human testing, leading to an even more urgent need to understand the role that cytokines and growth factors play in signaling cells to differentiate. In fact, there's a growing recognition that the ultimate pharma opportunity may lie in selling drug cocktails that control cell differentiation, not in making and selling cells. Because dormant adult stem cells reside in tissues and in circulation, researchers are even beginning to envision applications where transplanted replacement cells are not needed at all.
BioPharmaceutical Manufacturing

Targacept Inc.

Targacept spun out in 2000 from tobacco giant RJ Reynolds, with 60 patents, 23 scientists and an ongoing strategic alliance with Aventis. Not to mention $30 million from venture backers excited about the company's potential for discovering drugs that act on neuronal nicotinic receptors.
Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Layton BioScience Inc.
  • Senior Management
  • Gary L Snable, Pres. & CEO
    Robert Alonso, VP, Bus. Dev. & Mktg.
  • Contact Info
  • Layton BioScience Inc.
    Phone: (408) 616-1000
    709 E. Evelyn Ave.
    Sunnyvale, CA 95086
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register